The Trade: Bionano Genomics, Inc. (NASDAQ:BNGO) President and CEO R. Erik Holmlin acquired a total of 5025 shares at an average price of $3.99. The insider spent $20,037.25 to buy those shares. What’s Happening: On CNBC’s "Mad Money Lightning Round," Jim Cramer said Bionano Genomics is a good spec, but he actually likes CRISPR Therapeutics. What Bionano Genomics Does: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space.
•Oppenheimer says that Bionano Genomics (NASDAQ:BNGO) is a buy due to strong 2021 sales of its Saphyr System for genome imaging.
•The firm has a $14 price target on shares (332% upside based on Thursday's close).
•Analyst Kevin DeGeeter says that his estimate is for Bionano to place 156 Saphyr Systems this year, above the 150 target set by the company.
•Multiple clinical validation studies to support reimbursement are enrolling well and commercial adoption is leading to higher consumable pull-through that should impact 4Q21 and 2022," he writes.
oder Leiche? Leiche trifft es bei mir auch ganz gut. Auf Kursziele gebe ich nichts mehr. Wenn das Marktumfeld negativ ist, können die schreiben was sie wollen
Optimal genome mapping offers high-resolution method to better see, then target cancer-causing gene variants
...The standardization of the technique was necessary to establish precisely how to use OGM on patients to obtain consistently, accurate results.
Other investigators also have been exploring OGM's potential in specific cancers like acute lymphoblastic leukemias and larger groups of cancer types as well.
There already is some movement in places like Europe and Canada to move away from longtime approaches like FISH and move toward OGM. Kolhe hopes the newly published information about how to use OGM for patients will help do the same in this country.
Later this month, the Georgia Cancer Center will be the first to use OGM for patient care in the United States, Kolhe says. While many centers do not have the OGM technology, providers can send their patients' cells to MCG's Georgia Esoteric and Molecular Lab for testing effectively immediately...
die vorherigen Unternehmensmeldungen empfand ich als Laie positiv, aber der Kurs sackt stetig ab. Für unprofitable Wachstumsunternehmen ist das Umfeld ja grundsätzlich schlecht. Ob die Umsätze und Kosten sich schlechter als erwartet entwickelt haben, habe ich noch nicht gelesen.
Thread abonnieren
